Mar 07th 2013 - Edison Investment Research today published a report on quickview entitled "Cash Dash For NASH". In summary, the report says:
Genfit’s future success pivots on its ability to secure adequate funding for the ongoing Phase IIb trial of its lead product, GFT505, in non-alcoholic steatohepatitis (NASH). Some €25m is being sought to move the PPAR α/ agonist to ‘Phase III-ready’ stage. The robust Phase I/IIa package, the relative paucity of competition, and the lack of an approved treatment should make it an attractive asset to fund and/or partner. While the high prevalence of NASH implies a substantial opportunity, identifying patients for treatment may represent a challenge without a simple diagnostic test to fully open the commercial potential of this market.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
